Clinical Trial Update: DALY II Japan/MB-CART2019.1 for DLBCL [Phase 2]

View source ↗

Summary

A Phase 2 trial (DALY II Japan/MB-CART2019.1) by Miltenyi Biomedicine is evaluating MB-CART2019.1 for diffuse large B-cell lymphoma in Japan and is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• MB-CART2019.1

Snippet

Sponsor: Miltenyi Biomedicine GmbH | Conditions: DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy | Phase 2 | Status: RECRUITING